Clinical EvidenceNatera unveils groundbreaking data at ESMO, which strengthens its case for Signatera MRD inclusion into key NCCN guidelines.
Financial PerformanceRevenue of $413M (+58% y/y) came in above MSe/cons. $337/343M driven by an increase in testing volume, ASP per test, and OOP collections.
Market PositionNTRA remains the clear leader in the MRD testing market (a potentially large addressable opportunity).